Third-Party Tested • Batch-Specific COAs
Browse laboratory reports by product and sample lot identifier. Each report applies only to the sample identified in that report; it does not cover other strengths or batches.
Laboratory Reports
MZ Biolabs • Analysis date: September 18, 2026 • Report date: September 29, 2026 • Method: HPLC-UV-MS
| Product label | COA lot identifier | Reported purity | Report |
|---|---|---|---|
| Ipamorelin 10 mg | IP10 (clear/copper) | 99.60% | View COA (PDF) |
| KLOW Blend 80 mg | KL80 (clear/gold) | 99.86% | View COA (PDF) |
| NAD+ 500 mg | NJ500 (blue/silver) | 99.28% | View COA (PDF) |
| Retatrutide 10 mg | R10 (clear/silver) | 99.57% | View COA (PDF) |
| Retatrutide 20 mg | R20 (blue/silver) | 84.78% | View COA (PDF) |
| Retatrutide 30 mg | R30 (clear/silver) | 99.59% | View COA (PDF) |
| Tirzepatide 20 mg | T20 (white/silver) | 96.34% | View COA (PDF) |
| Tirzepatide 30 mg | T30 (pink/silver) | 99.93% | View COA (PDF) |
KLOW composition: The report identifies GHK-Cu, BPC-157, KPV, and TB-500 as thymosin beta-4 fragment 17–23. The 99.86% figure is the overall reported purity of the blend.
These reports document chromatographic purity and mass-spectrometry identity testing. They do not report vial-content quantity, sterility, endotoxins, or biological potency. Product amounts above are label descriptions, not independently verified quantities. Refer to each original report for the complete testing scope and results.